In September 2016, MedDay published the results from a phase 3 clinical trial (MS-SPI). This trial tested the effectiveness of MD1003 as a treatment for primary progressive or relapse-free secondary progressive MS.
The trial involved 144 people that took either:
- MD1003 (doses ranging from 100 - 600 mg) daily for 24 months
- a placebo for 12 months followed by 300 mg of MD1003 daily for 12 months
The trial primarily focused on how effective MD1003 was at improving disability (especially mobility) in people with progressive MS. Approximately 13% of people taking MD1003 experienced an improvement in disability after 9 months, which was maintained at 12 months. No one taking placebo experienced any improvement. Improvement in disability was measured by the Expanded Disability Status Scale (EDSS) or a timed 25-foot walk.